Fennec Pharmaceuticals Inc
FRX
Company Profile
Business description
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Contact
68 TW Alexander Drive
PO Box 13628
Research Triangle ParkNC27709
USAT: +1 919 636-4530
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
32
Stocks News & Analysis
stocks
The best way to get rich and retire early
This goes through the different options including shares, property and business ownership and declares a winner, as well as outlining the mindset needed to earn enough to never have to work again.
stocks
Investors too optimistic about ASX growth story
Investors have gotten ahead of themselves with shares trading at a 94% premium to fair value.
stocks
Stellar growth from ASX retailer but markets still too optimistic
This Australian success story looks set to face profit margin compression from the scariest of competitors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,150.30 | 32.70 | 0.36% |
| CAC 40 | 7,753.42 | 54.90 | 0.71% |
| DAX 40 | 24,024.78 | 56.56 | -0.23% |
| Dow JONES (US) | 44,458.61 | 483.52 | 1.10% |
| FTSE 100 | 9,147.81 | 18.10 | 0.20% |
| HKSE | 24,969.68 | 62.87 | 0.25% |
| NASDAQ | 21,681.90 | 296.50 | 1.39% |
| Nikkei 225 | 42,718.17 | 897.69 | 2.15% |
| NZX 50 Index | 12,813.51 | 53.83 | 0.42% |
| S&P 500 | 6,445.76 | 72.31 | 1.13% |
| S&P/ASX 200 | 8,880.80 | 36.00 | 0.41% |
| SSE Composite Index | 3,665.92 | 18.37 | 0.50% |